67 results about "Metal Chelator" patented technology

The present disclosure relates to the use of a metal chelator to treat an exposed photoresist film. In particular embodiments, the metal chelator is employed to remove an interfacial area that is disposed between exposed and unexposed areas or disposed within an exposed area, thereby enhancing patterning quality.

A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F / 18F exchange or a precursor thereof; and optionally a cell-targeting domain.

Provided herein are radiopharmaceuticals and conjugates, and compositions thereof targeting GPC3 and uses thereof. In one aspect, provided herein are conjugates that comprise a peptide with avidity to GPC3 and a metal chelator configured to bind with a radionuclide. The conjugates described herein can further comprise a linker connecting the chelator and the peptide. The conjugates described herein can further comprise a radionuclide. In one aspect, provided herein are radiopharmaceuticals that comprise a peptide and a metal chelator bound to a radionuclide. The conjugates described herein can further comprise a linker connecting the chelator and the peptide. Further provided herein are methods of treating cancer by administering the described radiopharmaceuticals, conjugates, compositions thereof.

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to PSMA, compositions thereof and uses thereof in methods of treatment.

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and / or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.

A chelator having formula I or a salt thereof removing metal ions from a solution is provided:wherein X1 is N or P; and n is 1 or 2. Protein-chelator systems for removing metal ions from a solution are also provided.

The present invention relates to compounds comprising a metal chelating agent and two fragments capable of binding to the somatostatin type 2 receptor, compositions thereof and their use in methods of treatment.

Provided herein are peptides and conjugates (e.g., radiopharmaceutical conjugates) having avidity for a somatostatin receptor and uses thereof. The conjugate can comprise a 6-mer peptide, such as a monocyclic 6-mer peptide, a metal chelator, and optionally a linker connecting the peptide to the chelator. The radiopharmaceutical conjugate can further comprise a radionuclide bound to the metal chelator. Further provided herein are methods of preparing the conjugates, and methods of treating cancer by administering the described conjugates to a subject in need thereof.

A microorganism engineered to: produce or overproduce auxin; reduce the production of ethylene; produce or overproduce one or more metal chelator molecules; and / or reduce or knockout the production of

Metal chelation compounds and associated coordination complexes are provided. In one aspect, this disclosure provides for a metal chelation compound, the compound having the general structure: D-L-T, wherein D is deferasirox or a derivative thereof, T is triapine or a derivative thereof, and L is a linking group and is a bond, C1-C10 alkyl, C2-C10 alkenyl, or —(C0-C3 alkyl)-R—(C0-C3 alkyl)-, wherein R is aryl, cycloalkyl, or polyethylene glycol.

The application provides a chemical detachable hydrogel electrode for physiological electrical measurement, a use method thereof, and the electrode comprises a flexible base layer, a flexible packaging layer, a flexible electrode array layer integrated with internal circuits and one or more electrode points, a hydrogel base layer, a detachable hydrogel interface layer, and separately stored polymer solution, metal ion anchoring solution and metal chelating agent solution; the flexible electrode array layer is arranged in a flexible frame body formed by the flexible base layer and the flexible packaging layer, the electrode points extend out of the flexible frame body, the hydrogel base layer covers the electrode points, the detachable hydrogel interface layer is detachably arranged on the hydrogel base layer, and the combination and detachment with the hydrogel base layer are realized through the polymer solution, the metal ion anchoring solution and the metal chelating agent solution. The electrode can realize the detachable hydrogel interface through chemical solution immersion, realize the repeated use of the electrode, and reduce the cross-infection risk.

The present invention has an object to provide a photosensitive resin composition which, when formed into a cured film, has high transparency and chemical resistance, low film stress, and high adhesion to a metal layer containing molybdenum, aluminum, or nickel. In order to solve the above object, the present invention provides a photosensitive resin composition comprising a siloxane resin having a radical polymerizable group, a metal chelating agent, and a photoradical polymerization initiator, wherein in the siloxane resin having a radical polymerizable group, (R) 2 SiO 2 / 2 The present invention proposes a photosensitive resin composition in which the content of organosilane units (D units) represented by (R is an organic group) is 30 mol % or more and 85 mol % or less relative to 100 mol % of all organosilane units.

The present invention provides for a metal chelator capable of binding a radioisotope or radionuclide, and bioconjugate thereof, and methods of making and using thereof.

The present invention relates to the technical field of biological material preservation, and particularly discloses an RNA preservation tube, which comprises: an amino acid component selected from at least one of glycine and a derivative thereof; the EDTA metal chelating agent is selected from at least one of EDTA alkali metal salts and hydrates thereof; a preservative component; optionally comprising a pH indicator; the storage tube is provided with a sealed cavity for storing an RNA solution, and the volume of the cavity is 1-20ml; through combination of a glycine-EDTA synergistic buffer system and an imidazolidinyl urea preservative, long-acting stable preservation of an RNA sample in an extreme environment is realized, metal ions can be dynamically chelated and the pH value is maintained in a range of 6.8-7.5 through a specific ratio of glycine to EDTA salt, a multi-protection mechanism is formed by combining a tube wall nucleic acid adsorption inhibition treatment technology, and the RNA sample can be stably preserved in the extreme environment through the combination of the glycine-EDTA synergistic buffer system and the imidazolidinyl urea preservative. And the loss caused by RNA enzyme activity, acid-base degradation and physical adsorption is effectively blocked, and the product is especially suitable for high-temperature transportation or long-term normal-temperature storage scenes.

Provided herein are radiopharmaceutical conjugate compositions and uses thereof. In one aspect, provided herein are conjugates that comprises a targeting ligand that covalently binds to a mutated or an overexpressed protein, optionally a linker, and a metal chelator. The conjugate can be configured to bind with a mutated or overexpressed protein inside a cell. Further provided herein are methods of treating cancer by administering the described conjugates and compositions.

The present disclosure relates to novel folic acid conjugates comprising 5-methyltetrahydrofolic acid, a radiometal chelator that optionally coordinates a radiometal M, and an albumin binder linked via a hydrophobic linker, and further provides uses of such conjugates and / or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy, or theragnostic applications.

Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

The present invention relates to the field of cell preservation fluid, and provides a cell preservation fluid and a red blood cell simulant, and a preparation method and application thereof. The cell preservation fluid comprises a polyphenol compound, a buffer system, a metal chelator, a nutrient, a metabolic regulator, mannitol, a poloxamer, and an optional preservative. The preparation method of the red blood cell simulant comprises the following steps: taking venous blood from a mammal and purifying it to obtain red blood cells; then fixing the obtained red blood cells with a fixative; and then dispersing the red blood cells obtained by the fixation in the cell preservation fluid of the present invention. The cell preservation fluid of the present invention is beneficial to improving the stability of red blood cells and maintaining good uniformity of red blood cells; the red blood cells in the red blood cell simulant of the present invention have good opening stability, thermal stability, and long-term stability, and the coefficient of variation of the red blood cells is low, and the product batch reproducibility is good.

A chelator having formula I or a salt thereof removing metal ions from a solution is provided: wherein X1 is N or P; and n is 1 or 2. Protein-chelator systems for removing metal ions from a solution are also provided.

The present technology relates to a method for analyzing a sample containing an analyte. The method includes injecting the sample containing the analyte into a mobile phase. The mobile phase contains a metal chelating agent additive at a concentration between about 1 ppm and about 10 ppm. The method further includes separating the analyte using liquid chromatography and analyzing the analyte using a mass spectrometer, an ultraviolet detector, or a combination thereof.

The present invention discloses a PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group and its preparation, which belongs to the technical fields of radiopharmaceuticals and medical imaging. The general formula of the PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group of the present invention is shown in Formula I and Formula II. The present invention is the first to link both a nitroaromatic group and a PSMA-targeting group to a metal chelator (such as HBED-CC, DOTA, DOTA(GA)2, NOTA, AAZTA, etc.) and to target a radiometal nuclide, e.g. 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 The radioactive metal marker is labeled with Bi, etc. The synergistic effect of the nitroaromatic heterocyclic group in vivo is expected to increase the uptake of the radioactive metal marker by prostate cancer, promoting metabolism in non-target organs and improving the therapeutic efficacy of radiopharmaceuticals against tumors. JPEG2026508753000106.jpg2835JPEG2026508753000107.jpg2145 (wherein the R1 and R2 groups are nitroaromatic heterocyclic groups; L2 is a linking group between the R1 group and L1, where L1 is a linking group between the chelator and the structure PSMA targeting structure; L4 is a linking group between the R2 group and L3, where L3 is a linking group between the chelator and the structure PSMA targeting structure; and ChelatoR1 and ChelatoR2 are chelators or chelating structures.)

Provided herein are methods of treating SSTR + cancer using radiopharmaceutical compositions. The radiopharmaceutical compositions may include one or more stabilizers, an aqueous vehicle, and a conjugate containing a targeting ligand and a radionuclide bound to a metal chelating agent. The targeting ligand may be a small molecule compound or peptide, such as a monocyclic peptide. The targeting ligand may be configured to bind to a tumor target. The stabilizers may include radiolytic stabilizers, free metal chelating agents, and / or pH stabilizers. Also provided herein are methods of making the radiopharmaceutical compositions and methods of treating cancer by administering the radiopharmaceutical compositions.

Disclosed is a method for preserving high molecular weight DNA in biological tissue, comprising contacting for a period of time at a temperature the biological tissue with an aqueous solution comprising a compound having the structure:

The present disclosure relates to novel folic acid conjugates comprising 5-methyltetrahydrofolic acid, a radiometal chelator that optionally coordinates a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of such conjugates and / or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy, or theragnostic applications.

Provided herein are a variety of metal chelators as well as methods of use thereof.

The present invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine diagnosis and treatment. Disclosed are a compound for dual targeting of a tumor cell, a preparation method therefor and the use thereof. The compound for dual targeting of a tumor cell has general formulas as represented by formula (I) and formula (II), wherein L1 and L3 are linking groups between a chelator and a PSMA-targeting structure; L2 and L4 are linking groups between the chelator and Peptide1; the Peptide1 and Peptide2 are polypeptide molecules having an SSTR2 targeting property, such as JR11, LM3, LM4, TATE, TOC and NOC; and Chelator1 and Chelator2 are chelators or chelating structures. In the present invention, a PSMA-targeting group and an SSTR2-targeting group are simultaneously linked to a metal chelator (HBED-CC, DOTAGA, DOTA(GA)2, etc.) for the first time for labeling a radioactive metal nuclide such as 68Ga, 18F-AlF, 177Lu, 90Y, 44Sc, 225Ac, 212Pb and 213Bi. The dual targeting function on PSMA and SSTR2 is beneficial to improving the lesion detection rate of neuroendocrine prostate cancer, and achieving more accurate tumor staging and disease prognosis, and is expected to be used for radionuclide targeted therapy.

The invention belongs to the technical field of electronic chemicals, and particularly discloses molybdenum etching liquid and application thereof in nanoscale molybdenum etching. The etching liquid comprises an alkaline solution, an oxidizing agent, a corrosion inhibitor and a metal chelating agent. The alkaline environment of the etching solution has efficient dissolving capacity, so that a stable etching rate can be maintained; meanwhile, the corrosion inhibitor and the chelating agent are added into the etching solution, the corrosion inhibitor can form a layer of thin film on the metal surface in a physical adsorption or chemical bond mode, so that the etching rate of the etching solution to the metal is stabilized and regulated, and the metal chelating agent can form a plurality of coordinate bonds with metal ions in the solution; therefore, a stable annular structure is formed, and the etching liquid is more stable. The etching solution designed by the invention is simple in component, uniform in etching effect and controllable in etching rate, can be used for nano-scale molybdenum etching, and is also suitable for etching multiple metal film layers such as molybdenum alloy.

Provided herein are methods of treating prostate cancer using radiopharmaceuticals. The radiopharmaceuticals compositions can comprise a prostate specific membrane antigen (PSMA) targeting moiety, a metal chelator, and a radionuclide chelated to the metal chelator.

Provided herein are a complex for diagnosing non-alcoholic steatohepatitis, use of the complex, and a contrast agent comprising the complex. The complex for diagnosing non-alcoholic steatohepatitis comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator. The complex is capable of binding to an asialoglycoprotein receptor, so that the complex has potential for use as a radiological diagnostic agent.

The invention discloses a flexible perovskite solar cell based on a metal chelating agent and a preparation method of the flexible perovskite solar cell. The flexible perovskite solar cell comprises a flexible transparent conductive substrate, an electron transport layer, a metal chelating agent molecule modification layer, a perovskite light absorption layer, a hole transport layer and an electrode which are sequentially arranged from bottom to top, wherein the metal chelating agent molecule modification layer adopts any one of EDTA-4Na and EGTA-4Na molecules, Na diffusion of the EDTA-4Na and the EGTA-4Na in the annealing process dopes the electron transport layer to improve the conductivity, and the EDTA-4Na molecules and the EGTA-4Na molecules interact with the perovskite light absorption layer and the electron transport layer to form passivation interface defects to improve the interface adhesion, so that the conductivity of the perovskite light absorption layer is improved. And a long chain of the EGTA-4Na molecule is used for absorbing stress in the bending process. The invention aims to improve the conductivity of the oxide electron transport layer, passivate the defects of the buried interface, improve the adhesion of the buried interface and finally improve the efficiency and stability of the flexible perovskite solar cell by introducing chelating molecule interface modification.